December 2028 Options Now Available For Gilead Sciences (GILD)

Options analytics for Gilead Sciences (GILD) show a $125 put bid at $19.30 (stock price $125.89), implying a net cost basis of $105.70 if assigned and a 63% probability the put expires worthless; that premium equates to a 15.44% return (5.18% annualized) on the cash commitment. On the call side a $135 covered-call bid of $19.55 would produce a 22.77% total return to December 2028 if called away, with a 43% chance of expiring worthless and a 15.53% (5.21% annualized) YieldBoost; implied volatilities are ~30% (put) and 29% (call) versus a 12-month realized volatility of 28%.

Analysis

Market structure: The current GILD option setup favors option premium collectors — cash‑secured put sellers and covered‑call writers capture a ~15.5% multi‑year YieldBoost (≈5.2% annualized) while taking on assignment risk. Implied vol (29–30%) sits ~1–2 pts above trailing realized (28%), so supply of downside protection is modestly expensive but not extreme; a persistent increase in IV to >35–40% would materially widen put/call premia and attract more sellers. Cross‑asset impacts are small but real: sustained option selling ties up cash reserves (liquidity drag) and mutes marginal equity volatility, with negligible immediate FX/commodity effects but measurable local impacts on equity‑volatility term structure and hedging flows into rates and money‑market instruments.

Risk assessment: Tail risks for GILD are asymmetric — a major regulatory setback or trial failure could drive a >30–50% drawdown, far outstripping current option premia; conversely, a positive surprise could leave covered‑call writers capped. Time horizons: days — theta decay favors sellers; weeks/months — vega and event risk dominate (earnings/trial windows); years — structural revenue/patent shifts determine realizable upside. Hidden dependencies include correlated biotech volatility and M&A chatter; catalysts to monitor: next 90 days of trial readouts, Q earnings, and any patent litigation updates.

Trade implications: Direct actionable plays are (A) cash‑secured sell of Dec‑2028 GILD 125 puts to target a 105.70 basis (probability of no assignment ~63%) sized 1–3% portfolio, (B) buy GILD and sell Dec‑2028 135 covered calls to cap upside for a 22.8% max return, or (C) use 125/115 put credit spreads to limit assignment risk (max loss ~$10/share). Entry timing: initiate on IV ≤32% and avoid opening leg ahead of known binary events; exit or hedge if IV >40% or price drops >20%.

Contrarian angles: The market underestimates the value of acquiring GILD at an effective 105.70 (≈16% below spot) as a deliberate entry — consensus treats these trades as income plays rather than low‑cost equity entries. Premiums appear slightly underpricing 1‑in‑10 tail downside (implied < realized tail risk), meaning naked put selling is cheap but exposes to fat tails. Historical parallels: large cap biotechs issued similar yields pre‑trial windows and then gap‑downed on binary misses; consequence — being assigned concentrated stock during a sector drawdown can force costly deleveraging. Therefore favor limited allocation and protective spreads over naked assignment when sizing >3% exposure.

Key Decisions for Investors

• Sell cash‑secured GILD Dec‑2028 125 puts to collect ~19.30 (effective basis 105.70). Size 1–3% of portfolio; set hard risk limit: buy back if GILD <100 (≈20% drawdown) or IV >45%.
• Buy GILD up to 1–3% of portfolio and sell Dec‑2028 135 covered calls (collect ~19.55) to target a capped 22.8% return to expiration; roll if share >140 or within 14 days of a binary catalyst.
• If unwilling to accept assignment, implement a Dec‑2028 125/115 put credit spread (sell 125, buy 115) sized 0.5–2% to cap downside to ~$10/share; close if spread cost >200% of initial credit or GILD <95.
• Reduce broad biotech ETF exposure (IBB) by 1–2% to fund option strategies in GILD and redeploy freed capital into defensive large‑cap healthcare (JNJ/PFE) to lower sector‑specific binary risk over the next 6–12 months.